跳到正文

国际动态

FDA、EMA、WHO 等境外监管与审批动态、跨国药企与出海进展。

2,602条精选相关主题监管政策企业与市场

最新精选

第 2241–2260 条 · 共 2,602 条
9月25日周五
9月24日周四
  1. FDA · 新闻稿78

    FDA 批准礼来 Onswik(insulin efsitora alfa-gobe)每周一次基础胰岛素,用于成人 2 型糖尿病

    FDA 批准礼来 Onswik(insulin efsitora alfa-gobe),一种每周一次的基础胰岛素注射,用于成人 2 型糖尿病患者。该消息由 PR Newswire 发布,材料仅提供标题与摘要,未披露具体临床数据或适应症细节。

    推荐理由:FDA 批准礼来每周一次基础胰岛素用于 2 型糖尿病成人,读者可了解该给药频率在基础胰岛素中的差异。

  2. FDA · 新闻稿78

    FDA 批准礼来 Onswik(insulin efsitora alfa-gobe)每周一次基础胰岛素,用于成人 2 型糖尿病

    FDA 批准礼来 Onswik(insulin efsitora alfa-gobe)上市,用于成人 2 型糖尿病的每周一次基础胰岛素注射治疗。该药为每周给药一次的基础胰岛素注射方案。

    推荐理由:FDA 批准礼来每周一次基础胰岛素用于 2 型糖尿病成人,读者可据此了解基础胰岛素给药频次的新选项。

  3. Matthew Herper67

    FDA 顾问委员会就 Grail 旗下 Galleri 多癌种血液筛查试验的三项投票问题给出结果:安全性问题 10 票赞成、0 票反对、0 票弃权;有效性问题 6 票赞成、4 票反对、0 票弃权;获益大于风险问题 7 票赞成、2 票反对、1 票弃权。

    引用Matthew Herper@matthewherper

    I'm live-tweeting the afternoon discussion of the FDA's advisory committee meeting on $GRAL's blood test to detect multiple types of cancer. This is a very interesting screening test. It definitely identifies cancers. But there are a good number of people who do not have cancer who will get a positive result, and a lot of patients who will get a negative result who do have cancer. One really big question is whether it's really right to say this test identifies cancer "early." And even tougher one is how to think about a test that might make patients skip existing screening tests -- that could mean, for instance, that more breast or colorectal cancers might be missed. The public hearing was very interesting. Some speakers, like Phil Castle from NCI, worried about the false negatives. There were also patients who felt they had been saved by the results of the test. I'll be threading my notes from the afternoon here. Forgive me for typos -- these things move fast.

    推荐理由:FDA 专家委员会对 Galleri 多癌种筛查试验的三项投票结果,呈现了有效性与获益风险上的分歧。